RegeneCore Biotech

Focus: RegeneCore Biotech is a China-based nanobody screening technology company developing early-stage therapeutics in respiratory and hematologic indications. The company operates as a pre-revenue biotech with a lean footprint focused on proprietary nanobody platform development.

Unknown

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Open Jobs

About RegeneCore Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow RegeneCore Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RC1416

Moderate to Severe Asthma

Phase 1

Clinical Trials (1)

NCT06911866A Phase Ib Study of RC1416 Injection

Phase 1

Help build intelligence for RegeneCore Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to proprietary nanobody screening platform, a differentiated modality with IP moat potential in an underexplored therapeutic area
Early-stage pipeline with Phase 2 programs in high-unmet-need respiratory diseases (COPD, asthma) and hematologic malignancies
Ground-floor opportunity at a China-based biotech with international development ambitions in underserved markets

Watch Out For

Severe data opacity: no disclosed funding, employee count, revenue, or founding date limits visibility into financial stability and runway
Minimal hiring activity (4 open roles, all recruitment-focused) and zero published research signal early organizational maturity or scientific output
Single lead program (RC1416) across multiple indications suggests narrow asset focus; no Phase 3 programs or commercial-stage products present execution risk

Generated by Claude from RegeneCore Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RC1416

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06067490A Phase I Study of RC1416 Injection

Phase 1

RJK-RT2831 dose-escalation phase Ia

Hematologic Malignancies

Phase 1

Clinical Trials (1)

NCT06756451This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

Phase 1